Provectus Pharmaceuticals specializes in developing oncology and dermatology therapies. The company’s oncology drug PV-10 is designed to target and destroy cancer cells without harming surrounding healthy tissue while its dermatological drug PH-10 targets abnormal or diseased cells. Provectus recently completed phase 2 clinical trials of PV-10 as a therapy for metastatic melanoma and of PH-10 as a topical treatment for atopic dermatitis and psoriasis. For more information, visit the company’s website at www.pvct.com.